NASDAQ:DRUG - CA10919W4056 - Common Stock
The current stock price of DRUG is 48.43 USD. In the past month the price increased by 6.79%. In the past year, price increased by 3207.45%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.87 | 390.46B | ||
AMGN | AMGEN INC | 12.96 | 152.12B | ||
GILD | GILEAD SCIENCES INC | 15.15 | 145.47B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.4 | 101.64B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 61.37B | ||
REGN | REGENERON PHARMACEUTICALS | 12.44 | 60.18B | ||
ARGX | ARGENX SE - ADR | 81.97 | 46.51B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.86 | 39.84B | ||
INSM | INSMED INC | N/A | 30.76B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.93B | ||
NTRA | NATERA INC | N/A | 23.62B | ||
BIIB | BIOGEN INC | 9.15 | 21.48B |
Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company is headquartered in New York City, New York and currently employs 0 full-time employees. The company went IPO on 2021-02-08. The firm is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The firm has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.
BRIGHT MINDS BIOSCIENCES INC
19 Vestry Street
New York City NEW YORK US
Employees: 0
Phone: 16478658622
The current stock price of DRUG is 48.43 USD. The price increased by 14.84% in the last trading session.
The exchange symbol of BRIGHT MINDS BIOSCIENCES INC is DRUG and it is listed on the Nasdaq exchange.
DRUG stock is listed on the Nasdaq exchange.
BRIGHT MINDS BIOSCIENCES INC (DRUG) has a market capitalization of 342.88M USD. This makes DRUG a Small Cap stock.
BRIGHT MINDS BIOSCIENCES INC (DRUG) currently has 0 employees.
BRIGHT MINDS BIOSCIENCES INC (DRUG) has a support level at 41.94 and a resistance level at 43.61. Check the full technical report for a detailed analysis of DRUG support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
DRUG does not pay a dividend.
BRIGHT MINDS BIOSCIENCES INC (DRUG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.39).
The outstanding short interest for BRIGHT MINDS BIOSCIENCES INC (DRUG) is 3.98% of its float. Check the ownership tab for more information on the DRUG short interest.
ChartMill assigns a technical rating of 9 / 10 to DRUG. When comparing the yearly performance of all stocks, DRUG is one of the better performing stocks in the market, outperforming 99.92% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to DRUG. DRUG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months DRUG reported a non-GAAP Earnings per Share(EPS) of -0.39. The EPS increased by 60.66% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -6.1% | ||
ROE | -6.18% | ||
Debt/Equity | 0 |